West China School of Basic Medical Sciences & Forensic Medicine, Sichuan University, Chengdu 610041, China.
West China Second University Hospital, Sichuan University, Chengdu 610041, China.
Radiat Res. 2022 Sep 1;198(3):306-317. doi: 10.1667/RADE-22-00058.1.
COVID-19 is a challenge to biosecurity and public health. The speed of vaccine development lags behind that of virus evolution and mutation. To date, no agent has been demonstrated to be fully effective against COVID-19. Therefore, it remains of great urgency to rapidly develop promising therapeutic and diagnostic candidates. Intriguingly, mounting evidence hints at parallel etiologies between SARS-CoV-2 infection and radiation injury. Herein, from the perspectives of immunogenic pathway activation and metabolic alterations, we provide novel evidence of commonalities between these two pathological conditions based on the most recent findings. Since numerous agents have been developed to prevent or reverse radiation injury in the past 70 years to ensure nuclear safety, we also advocate investigating the promising function of radioprotectors and radiomitigators against COVID-19 in clinical settings.
新型冠状病毒肺炎对生物安全和公共卫生提出了挑战。疫苗的研发速度落后于病毒的进化和变异。迄今为止，还没有一种药物被证明对新型冠状病毒肺炎有完全的疗效。因此，迅速开发有前途的治疗和诊断候选药物仍然非常紧迫。有趣的是，越来越多的证据表明，SARS-CoV-2 感染和辐射损伤之间存在平行的病因。在此，我们根据最新的研究结果，从免疫原性途径激活和代谢改变的角度，为这两种病理状况之间的相似性提供了新的证据。由于在过去的 70 年里，为了确保核安全，已经开发了许多预防或逆转辐射损伤的药物，因此我们也提倡在临床环境中研究辐射防护剂和辐射减毒剂对新型冠状病毒肺炎的潜在作用。
